JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

JNJ

228.84

+1.19%↑

UNH

367.62

-0.09%↓

TMO

474.23

+1.58%↑

ISRG

452.39

+0.43%↑

ABT

90.42

-2.03%↓

Search

Compugen Ltd

Uždarymo kaina

2.58 -5.49

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.52

Max

2.71

Pagrindiniai rodikliai

By Trading Economics

Pajamos

64M

57M

Pardavimai

65M

67M

P/E

Sektoriaus vid.

7.684

67.147

Pelno marža

84.425

Darbuotojai

75

EBITDA

63M

56M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+71.06% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-18

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

64M

276M

Ankstesnė atidarymo kaina

8.07

Ankstesnė uždarymo kaina

2.58

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-29 23:53; UTC

Uždarbis

Naver Posts Weaker First-Quarter Earnings

2026-04-29 23:41; UTC

Karštos akcijos

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

2026-04-29 23:55; UTC

Uždarbis

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-29 23:54; UTC

Uždarbis

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

2026-04-29 23:52; UTC

Uždarbis

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

2026-04-29 23:51; UTC

Uždarbis

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

2026-04-29 23:51; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

2026-04-29 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Likely Technical Recovery -- Market Talk

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

2026-04-29 23:24; UTC

Uždarbis

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

2026-04-29 23:22; UTC

Uždarbis

China Longyuan 1Q Net CNY1.70B, Down 14%

2026-04-29 23:22; UTC

Uždarbis

China Longyuan: Power Generation Down 2.9% as of End-March

2026-04-29 23:20; UTC

Uždarbis

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

2026-04-29 23:20; UTC

Uždarbis

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

2026-04-29 23:19; UTC

Uždarbis

China Vanke 1Q Loss Narrows>000002.SZ

2026-04-29 23:18; UTC

Uždarbis

Naver1Q Net Profit Missed FactSet-Compiled Consensus

2026-04-29 23:17; UTC

Uždarbis

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

2026-04-29 23:15; UTC

Uždarbis

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

2026-04-29 23:13; UTC

Uždarbis

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

2026-04-29 23:12; UTC

Uždarbis

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

2026-04-29 23:11; UTC

Uždarbis

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

2026-04-29 23:04; UTC

Uždarbis

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

2026-04-29 23:04; UTC

Uždarbis

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

71.06% į viršų

12 mėnesių prognozė

Vidutinis 4.67 USD  71.06%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.25 / 1.48Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat